| Myocardial Protective Effect of Cardioxane for the Myocardial Damage due to Doxorubicin |
|
Hee-Ju Park1, Jai-Min Oh1, Sung-Hoon Kim1, Chang-Hoon Lee2, Sang-Sik Kim3 |
1Department of Pediatrics, College of Medicine, Pusan National University, Busan, Korea
2Department of Surgical Pathology, College of Medicine, Pusan National University, Busan, Korea
3Department of Technician of Electronic Microscopy, College of Medicine, Pusan National University, Busan, Korea |
| Doxorubicin의 심근 손상에 대한 Cardioxane의 예방 효과에 관한 연구 |
|
박희주1, 오재민1, 김성훈1, 이창훈2, 김상식3 |
1부산대학교 의과대학 소아과학교실
2부산대학교 의과대학 해부병리교실
3부산대학교 의과대학 전자 현미경실 |
Correspondence:
Hee-Ju Park, Email: phj7294@hanmail.net
|
|
|
|
|
| Abstract |
Purpose
: To find out the myocardial protective effect of cardioxane for the myocardial damage by doxorubicin.
Methods
: Using Eighteen rabbits(2.0-3.2 kg), doxorubicin(30 mg/m2) was injected intravenously once a week in group I(12 rabbits) and cardioxane(600 mg/m2) was injected at 20-30 minutes before doxorubicin administration in group II(6 rabbits). After this, we operated on the rabbits when the total cumulative dose of doxorubicin was reached at 210, 240, 270 and 300 mg/m2 and observed the degree of myocardial damage with light and electronic microscope.
Results
: In group I, rabbits with less than 210 mg/m2 of total cumulative dose of doxorubicin, there was no definite myocardial damage but with 240 mg/m2, focal degenerative change was observed and with 300 mg/m2, severe degenerative change was detected with light microscopic examination. With electronic microscope, rabbits with less than 180 mg/m2 of total cumulative dose of doxorubicin in group I, there was no evidence of myocardial damage. In 210 mg/m2, focal degenerative change was detected. With 240 mg/m2, degenerative change was much more advanced and with 300 mg/m2, severe degenerative change was detected. In group II, no definite myocardial damage was observed even though the total cumulative dose of doxorubicin reached 300 mg/m2, but with 360 mg/m2, there was a focal area where myocardial fibers were somewhat decreased, but it's difficult to say whether these decrement were due to adriamycin in the electronic microscopic examination.
Conclusion
: Cardioxane have a good protective effect for the doxorubicin induced cardiomyopathy and it will be used safely in pediatric cancer patients. |
| Key Words:
Cardioxane, Doxorubicin, Myocardial degenerative change |
|
PDF Links
Download Citation
